Please make the following amendments in the Specification.

Page 1, under the title, please add the following:

GOVERNMENT SUPPORT

A1 This invention was made with Government support under contract AI40093 awarded by the National Institute of Allergies and Infectious Diseases. The Government has certain rights in this invention.

Paragraphs 13-17, please replace with the following paragraphs:

[13] Figures 1A-L show ~~shows~~ a flow cytometric analysis of CD1 expression on splenic B cells. Spleen cells from 6-month-old C57BL/6 mice (A-C), 6-month-old NZB/NZW mice with proteinuria (D-F), 3-month-old C57BL/6 mice (G-I) and 3-month-old NZB/NZW mice (J-L) were stained with anti-B220-FITC or anti-IgM-FITC versus anti-CD1-Biotin (3C11 or 1B1) and counter-stained with streptavidin-PE. A subset of $B220^{+}CD1^{hi}$ or $IgM^{+}CD1^{hi}$ B cells is enclosed in the right box or upper-right box in each panel, and the percentage of $CD1^{hi}$ B cells among live nucleated cells is shown for each box. The $IgM^{-}CD1^{hi}$ B cells are enclosed in the lower-right box in each panel. Each panel is representative of at least four replicate experiments.

[14] Figures 2 A, B and C illustrate ~~illustrates~~ spontaneous secretion of IgM antibodies by $CD1^{hi}$ B cells. Panel A shows gates for spleen cells from 6-month-old NZB/NZW mice without proteinuria after staining with anti-B220-FITC versus anti-CD1 (1B1)-PE and sorting into $B220^{+}CD1^{lo}$, $B220^{+}CD1^{int}$ and $B220^{+}CD1^{hi}$ subsets. The percentage of cells amongst live nucleated cells is shown for each gate. Panels B and C show concentration of IgM and IgM anti-dsDNA antibodies, respectively, in culture supernatants of each subset ($5x10^5$ cells/well) with or without syngeneic T cells ($1.25x10^5$ cells/well). Data shows the Mean ± SE of six cultures from two experiments.

A2

[15] Figures 3 A and B show ~~shows~~ the spontaneous secretion of IgM and IgG by IgM^{+} and $B220^{+}$ B cells. Panels A and B show respectively the IgM and IgG production by sorted splenic $B220^{+}$ and IgM^{+} B cells ($5x10^5$ cells/well) from 6-month old NZB/NZW mice with proteinuria (≥ 3+). Data shows the Mean ± SE of six cultures from two experiments.

[16] Figures 4 A, B and C illustrate ~~illustrates~~ the proliferation of T cells in response to stimulation by CD1 transfected A20 cells. Panels A and B show the expression of CD1 on A20 cells, a B cell lymphoma line, and CD1 transfected A20 cells (A20/CD1) by staining the

cells with anti-B220 versus anti-CD1 mAbs. Panel C shows the proliferation of sorted splenic T (Thy1.2$^+$) cells (1x10^5/well) from 3-month old NZB/NZW mice co-cultured with the irradiated (5000 rads), graded numbers of A20 or A20/CD1 cells as measured with ^{3}H-TdR incorporation. Each panel is representative of three replicate experiments.

[17] Figures 5 A, B and C depict ~~depicts~~ the amelioration of lupus by *in vivo* anti-CD1 mAb treatment. Groups of 8-week old NZB/NZW mice were given 5 i.p. injections of anti-CD1 mAb or control rat IgG at a dose of 250 µg/mouse over a period of 30 days (days 0, 3, 5, 15 and 30). Thereafter, the mice were monitored with serum levels of IgG and anti-dsDNA IgG, and proteinuria and survival as shown in Panels A, B, C and D, respectively. There were 10 mice in each group. Arrows show time points of injections.